OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
Francesco Angotzi, Marco Petrella, Tamara Berno, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Francesco Angotzi, Marco Petrella, Tamara Berno, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Showing 7 citing articles:
The evolving landscape of COVID ‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC , the European research initiative on CLL
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1856-1868
Open Access | Times Cited: 14
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1856-1868
Open Access | Times Cited: 14
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response
Krischan Braitsch, Samuel Jeske, Jacob Stroh, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 871-871
Open Access | Times Cited: 1
Krischan Braitsch, Samuel Jeske, Jacob Stroh, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 871-871
Open Access | Times Cited: 1
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Ivo Demel, David Skopal, Eliška Šafránková, et al.
Annals of Hematology (2023) Vol. 103, Iss. 3, pp. 981-992
Open Access | Times Cited: 2
Ivo Demel, David Skopal, Eliška Šafránková, et al.
Annals of Hematology (2023) Vol. 103, Iss. 3, pp. 981-992
Open Access | Times Cited: 2
Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience
Andrea Cona, Alessandro Tavelli, Stefano Agrenzano, et al.
Microorganisms (2024) Vol. 12, Iss. 7, pp. 1436-1436
Open Access
Andrea Cona, Alessandro Tavelli, Stefano Agrenzano, et al.
Microorganisms (2024) Vol. 12, Iss. 7, pp. 1436-1436
Open Access
The Reply
Mohanad Al‐Obaidi, Bekir Tanrıöver, Tirdad T. Zangeneh
The American Journal of Medicine (2024) Vol. 137, Iss. 2, pp. e42-e42
Open Access
Mohanad Al‐Obaidi, Bekir Tanrıöver, Tirdad T. Zangeneh
The American Journal of Medicine (2024) Vol. 137, Iss. 2, pp. e42-e42
Open Access
Covid-19 : mise à jour des stratégies thérapeutiques curatives précoces et du patient sous oxygénothérapie
Karim Jaffal, Benjamin Davido
Revue des Maladies Respiratoires (2023) Vol. 41, Iss. 1, pp. 51-58
Closed Access
Karim Jaffal, Benjamin Davido
Revue des Maladies Respiratoires (2023) Vol. 41, Iss. 1, pp. 51-58
Closed Access
